

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

	FOURTH QUARTER				
	2014	2013	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$ 1,294	1,263	2.5 %	2.5	-
International	2,312	2,490	(7.1)	0.1	(7.2)
	3,606	3,753	(3.9)	0.9	(4.8)
Pharmaceutical					
U.S.	4,356	3,551	22.7	22.7	-
International	3,643	3,745	(2.7)	5.8	(8.5)
	7,999	7,296	9.6	13.9	(4.3)
Medical Devices					
U.S.	2,954	3,200	(7.7)	(7.7)	-
International	3,695	4,106	(10.0)	(2.3)	(7.7)
	6,649	7,306	(9.0)	(4.7)	(4.3)
U.S.	8,604	8,014	7.4	7.4	-
International	9,650	10,341	(6.7)	1.2	(7.9)
Worldwide	\$ 18,254	18,355	(0.6) %	3.9	(4.5)

	TWELVE MONTHS				
	2014	2013	Total	Percent Change	
				Operations	Currency
Consumer					
U.S.	\$ 5,096	5,162	(1.3) %	(1.3)	-
International	9,400	9,535	(1.4)	2.3	(3.7)
	14,496	14,697	(1.4)	1.0	(2.4)
Pharmaceutical					
U.S.	17,432	13,948	25.0	25.0	-
International	14,881	14,177	5.0	8.3	(3.3)
	32,313	28,125	14.9	16.5	(1.6)
Medical Devices					
U.S.	12,254	12,800	(4.3)	(4.3)	-
International	15,268	15,690	(2.7)	0.5	(3.2)
	27,522	28,490	(3.4)	(1.6)	(1.8)
U.S.	34,782	31,910	9.0	9.0	-
International	39,549	39,402	0.4	3.7	(3.3)
Worldwide	\$ 74,331	71,312	4.2 %	6.1	(1.9)

Johnson & Johnson and Subsidiaries**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	FOURTH QUARTER				
	2014	2013	Percent Change		
			Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 8,604	8,014	7.4 %	7.4	-
Europe	4,560	4,968	(8.2)	0.6	(8.8)
Western Hemisphere excluding U.S.	1,782	1,891	(5.8)	3.9	(9.7)
Asia-Pacific, Africa	3,308	3,482	(5.0)	0.6	(5.6)
International	9,650	10,341	(6.7)	1.2	(7.9)
Worldwide	\$ 18,254	18,355	(0.6) %	3.9	(4.5)

	TWELVE MONTHS				
	2014	2013	Percent Change		
			Total	Operations	Currency
	\$ 34,782	31,910	9.0 %	9.0	-
	18,947	18,599	1.9	2.6	(0.7)
	7,160	7,421	(3.5)	5.2	(8.7)
	13,442	13,382	0.4	4.4	(4.0)
	39,549	39,402	0.4	3.7	(3.3)
	\$ 74,331	71,312	4.2 %	6.1	(1.9)

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER

	2014		2013		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 18,254	100.0	\$ 18,355	100.0	(0.6)
Cost of products sold	5,853	32.1	5,955	32.5	(1.7)
Selling, marketing and administrative expenses	5,822	31.9	5,917	32.2	(1.6)
Research and development expense	2,635	14.4	2,411	13.1	9.3
In-process research and development	156	0.8	338	1.9	
Interest (income) expense, net	122	0.7	116	0.6	
Other (income) expense, net	963	5.3	868	4.7	
Earnings before provision for taxes on income	2,703	14.8	2,750	15.0	(1.7)
Provision for/(Benefit from) taxes on income	182	1.0	(769)	(4.2)	
Net earnings	\$ 2,521	13.8	\$ 3,519	19.2	(28.4)
Net earnings per share (Diluted)	\$ 0.89		\$ 1.23		(27.6)
Average shares outstanding (Diluted)	2,845.3		2,872.0		
Effective tax rate	6.7 %		(28.0) %		
Adjusted earnings before provision for taxes and net earnings ⁽¹⁾					
Earnings before provision for taxes on income	\$ 3,925	21.5	\$ 3,909	21.3	0.4
Net earnings	\$ 3,612	19.8	\$ 3,561	19.4	1.4
Net earnings per share (Diluted)	\$ 1.27		\$ 1.24		2.4
Effective tax rate	8.0 %		8.9 %		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS

	2014		2013		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 74,331	100.0	\$ 71,312	100.0	4.2
Cost of products sold	22,746	30.6	22,342	31.3	1.8
Selling, marketing and administrative expenses	21,954	29.5	21,830	30.6	0.6
Research and development expense	8,494	11.4	8,183	11.5	3.8
In-process research and development	178	0.3	580	0.8	
Interest (income) expense, net	466	0.6	408	0.6	
Other (income) expense, net	(70)	(0.1)	2,498	3.5	
Earnings before provision for taxes on income	20,563	27.7	15,471	21.7	32.9
Provision for taxes on income	4,240	5.7	1,640	2.3	
Net earnings	\$ 16,323	22.0	\$ 13,831	19.4	18.0
Net earnings per share (Diluted)	\$ 5.70		\$ 4.81		18.5
Average shares outstanding (Diluted)	2,863.9		2,877.0		
Effective tax rate	20.6 %		10.6 %		
Adjusted earnings before provision for taxes and net earnings ⁽¹⁾					
Earnings before provision for taxes on income	\$ 21,195	28.5	\$ 19,169	26.9	10.6
Net earnings	\$ 17,105	23.0	\$ 15,876	22.3	7.7
Net earnings per share (Diluted)	\$ 5.97		\$ 5.52		8.2
Effective tax rate	19.3 %		17.2 %		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

<i>(Dollars in Millions Except Per Share Data)</i>	Fourth Quarter		% Incr. / (Decr.)	Twelve Months		% Incr. / (Decr.)
	2014	2013		2014	2013	
Earnings before provision for taxes on income - as reported	\$ 2,703	2,750	(1.7) %	\$ 20,563	15,471	32.9 %
Ortho-Clinical Diagnostics divestiture net (gain)/expense	49	-		(1,899)	-	
Litigation expenses	692	506		1,253	2,282	
Synthes integration/transaction costs	325	181		754	683	
Additional year of Branded Prescription Drug Fee	-	-		220	-	
In-process research and development	156	338		178	580	
DePuy ASR™ Hip program	-	134		126	251	
Other	-	-		-	(98)	
Earnings before provision for taxes on income - as adjusted	<u>\$ 3,925</u>	<u>3,909</u>	<u>0.4 %</u>	<u>\$ 21,195</u>	<u>19,169</u>	<u>10.6 %</u>
Net Earnings - as reported	\$ 2,521	3,519	(28.4) %	\$ 16,323	13,831	18.0 %
Ortho-Clinical Diagnostics divestiture net (gain)/expense	87	-		(1,062)	-	
Litigation expenses	652	227		1,225 (1)	1,646	
Synthes integration/transaction costs	237	110		555	483	
Additional year of Branded Prescription Drug Fee	-	-		220	-	
In-process research and development	115	294		131	462	
DePuy ASR™ Hip program	-	118		111	240	
Tax benefit associated with Conor Medsystems	-	-		(398)	-	
Scios tax benefit	-	(707)		-	(707)	
Other	-	-		-	(79)	
Net Earnings - as adjusted	<u>\$ 3,612</u>	<u>3,561</u>	<u>1.4 %</u>	<u>\$ 17,105</u>	<u>15,876</u>	<u>7.7 %</u>
Diluted Net Earnings per share - as reported	\$ 0.89	1.23	(27.6) %	\$ 5.70	4.81	18.5 %
Ortho-Clinical Diagnostics divestiture net (gain)/expense	0.03	-		(0.37)	-	
Litigation expenses	0.23	0.08		0.43	0.57	
Synthes integration/transaction costs	0.08	0.04		0.19	0.17	
Additional year of Branded Prescription Drug Fee	-	-		0.08	-	
In-process research and development	0.04	0.10		0.04	0.16	
DePuy ASR™ Hip program	-	0.04		0.04	0.08	
Tax benefit associated with Conor Medsystems	-	-		(0.14)	-	
Scios Tax Benefit	-	(0.25)		-	(0.25)	
Other	-	-		-	(0.02)	
Diluted Net Earnings per share - as adjusted	<u>\$ 1.27</u>	<u>1.24</u>	<u>2.4 %</u>	<u>\$ 5.97</u>	<u>5.52</u>	<u>8.2 %</u>

(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions and Divestitures

FOURTH QUARTER 2014 ACTUAL vs. 2013 ACTUAL

	Segments			
	Operational % ⁽¹⁾			
	Consumer	Pharmaceutical	Medical Devices	Total
WW As Reported:	0.9%	13.9%	(4.7)%	3.9%
U.S.	2.5%	22.7%	(7.7)%	7.4%
International	0.1%	5.8%	(2.3)%	1.2%
Women's Health				
<i>Sanitary Protection</i>	0.5			0.1
U.S.	1.4			0.2
International	0.1			0.0
Women's Health				
<i>K-Y</i> [®]	0.5			0.2
U.S.	1.0			0.2
International	0.3			0.1
Diagnostics				
<i>Ortho-Clinical Diagnostics</i>			6.2	2.5
U.S.			6.7	2.9
International			5.8	2.3
All Other Acquisitions and Divestitures	0.2			0.0
U.S.	0.0			0.0
International	0.2			0.0
WW Ops excluding Acquisitions and Divestitures	2.1%	13.9%	1.5%	6.7%
U.S.	4.9%	22.7%	(1.0)%	10.7%
International	0.7%	5.8%	3.5%	3.6%

⁽¹⁾ Operational growth excludes the effect of translational currency

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions and Divestitures

TWELVE MONTHS 2014 ACTUAL vs. 2013 ACTUAL

	Segments			
	Operational % ⁽¹⁾			
	<u>Consumer</u>	<u>Pharmaceutical</u>	<u>Medical Devices</u>	<u>Total</u>
WW As Reported:	1.0%	16.5%	(1.6)%	6.1%
U.S.	(1.3)%	25.0%	(4.3)%	9.0%
International	2.3%	8.3%	0.5%	3.7%
Women's Health				
<i>Sanitary Protection</i>	1.4			0.3
U.S.	3.8			0.6
International	0.1			0.0
Women's Health				
<i>K-Y</i> [®]	0.3			0.1
U.S.	0.6			0.1
International	0.1			0.0
Diagnostics				
<i>Ortho-Clinical Diagnostics</i>			3.2	1.4
U.S.			3.7	1.8
International			3.0	1.2
All Other Acquisitions and Divestitures	0.1	0.1		0.1
U.S.	0.0	0.1		0.1
International	0.1	0.1		0.2
WW Ops excluding Acquisitions and Divestitures	2.8%	16.6%	1.6%	8.0%
U.S.	3.1%	25.1%	(0.6)%	11.6%
International	2.6%	8.4%	3.5%	5.1%

⁽¹⁾ Operational growth excludes the effect of translational currency



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency
CONSUMER SEGMENT⁽²⁾										
BABY CARE										
US	\$ 96	105	-8.6%	-8.6%	-	\$ 407	413	-1.5%	-1.5%	-
Intl	428	480	-10.8%	-4.8%	-6.0%	1,832	1,882	-2.7%	1.8%	-4.5%
WW	524	585	-10.4%	-5.5%	-4.9%	2,239	2,295	-2.4%	1.3%	-3.7%
ORAL CARE										
US	150	153	-2.0%	-2.0%	-	600	602	-0.3%	-0.3%	-
Intl	264	265	-0.4%	6.1%	-6.5%	1,047	1,020	2.6%	5.9%	-3.3%
WW	414	418	-1.0%	3.1%	-4.1%	1,647	1,622	1.5%	3.6%	-2.1%
OTC										
US	362	332	9.0%	9.0%	-	1,357	1,286	5.5%	5.5%	-
Intl	711	747	-4.8%	3.6%	-8.4%	2,749	2,742	0.3%	3.7%	-3.4%
WW	1,073	1,079	-0.6%	5.2%	-5.8%	4,106	4,028	1.9%	4.2%	-2.3%
SKIN CARE										
US	471	432	9.0%	9.0%	-	1,834	1,752	4.7%	4.7%	-
Intl	485	538	-9.9%	-3.7%	-6.2%	1,924	1,952	-1.4%	1.2%	-2.6%
WW	956	970	-1.4%	2.0%	-3.4%	3,758	3,704	1.5%	2.9%	-1.4%
WOMEN'S HEALTH										
US	7	38	-81.6%	-81.6%	-	50	280	-82.1%	-82.1%	-
Intl	301	310	-2.9%	6.0%	-8.9%	1,252	1,288	-2.8%	2.6%	-5.4%
WW	308	348	-11.5%	-3.6%	-7.9%	1,302	1,568	-17.0%	-12.6%	-4.4%
WOUND CARE/OTHER										
US	208	203	2.5%	2.5%	-	848	829	2.3%	2.3%	-
Intl	123	150	-18.0%	-11.6%	-6.4%	596	651	-8.4%	-6.3%	-2.1%
WW	331	353	-6.2%	-3.5%	-2.7%	1,444	1,480	-2.4%	-1.5%	-0.9%
TOTAL CONSUMER										
US	1,294	1,263	2.5%	2.5%	-	5,096	5,162	-1.3%	-1.3%	-
Intl	2,312	2,490	-7.1%	0.1%	-7.2%	9,400	9,535	-1.4%	2.3%	-3.7%
WW	\$ 3,606	3,753	-3.9%	0.9%	-4.8%	\$ 14,496	14,697	-1.4%	1.0%	-2.4%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT^{(2),(3)}										
IMMUNOLOGY										
US	\$ 1,816	1,726	5.2%	5.2%	-	\$ 7,111	6,591	7.9%	7.9%	-
Intl	762	676	12.7%	22.2%	-9.5%	3,082	2,599	18.6%	23.3%	-4.7%
WW	2,578	2,402	7.3%	10.0%	-2.7%	10,193	9,190	10.9%	12.2%	-1.3%
REMICADE										
US	\$ 1,052	982	7.1%	7.1%	-	4,155	3,891	6.8%	6.8%	-
US Exports ⁽⁴⁾	244	367	-33.5%	-33.5%	-	1,078	1,339	-19.5%	-19.5%	-
Intl	376	363	3.6%	12.6%	-9.0%	1,635	1,443	13.3%	19.0%	-5.7%
WW	1,672	1,712	-2.3%	-0.4%	-1.9%	6,868	6,673	2.9%	4.1%	-1.2%
SIMPONI/SIMPONIARIA										
US	164	112	46.4%	46.4%	-	544	404	34.7%	34.7%	-
Intl	182	142	28.2%	39.0%	-10.8%	643	528	21.8%	26.4%	-4.6%
WW	346	254	36.2%	42.2%	-6.0%	1,187	932	27.4%	30.0%	-2.6%
STELARA										
US	356	265	34.3%	34.3%	-	1,334	957	39.4%	39.4%	-
Intl	189	152	24.3%	34.3%	-10.0%	738	547	34.9%	37.3%	-2.4%
WW	545	417	30.7%	34.4%	-3.7%	2,072	1,504	37.8%	38.7%	-0.9%
OTHER IMMUNOLOGY										
US	-	-	-	-	-	-	-	-	-	-
Intl	15	19	-21.1%	-15.9%	-5.2%	66	81	-18.5%	-14.3%	-4.2%
WW	15	19	-21.1%	-15.9%	-5.2%	66	81	-18.5%	-14.3%	-4.2%
INFECTIOUS DISEASES										
US	564	302	86.8%	86.8%	-	3,112	1,077	*	*	-
Intl	512	642	-20.2%	-12.1%	-8.1%	2,487	2,473	0.6%	2.5%	-1.9%
WW	1,076	944	14.0%	19.5%	-5.5%	5,599	3,550	57.7%	58.6%	-0.9%
EDURANT										
US	6	5	20.0%	20.0%	-	24	15	60.0%	60.0%	-
Intl	84	68	23.5%	33.8%	-10.3%	341	221	54.3%	54.3%	0.0%
WW	90	73	23.3%	32.9%	-9.6%	365	236	54.7%	54.7%	0.0%
INCIVO										
US	-	-	-	-	-	-	-	-	-	-
Intl	5	107	-95.3%	-90.7%	-4.6%	226	517	-56.3%	-55.0%	-1.3%
WW	5	107	-95.3%	-90.7%	-4.6%	226	517	-56.3%	-55.0%	-1.3%
OLYSIO/SOVRIAD										
US	256	13	*	*	-	1,943	13	*	*	-
Intl	65	10	*	*	-12.5%	359	10	*	*	-2.3%
WW	321	23	*	*	-2.5%	2,302	23	*	*	-0.4%
PREZISTA										
US	243	229	6.1%	6.1%	-	930	807	15.2%	15.2%	-
Intl	205	232	-11.6%	-3.5%	-8.1%	901	866	4.0%	5.9%	-1.9%
WW	448	461	-2.8%	1.3%	-4.1%	1,831	1,673	9.4%	10.4%	-1.0%
OTHER INFECTIOUS DISEASES										
US	59	55	7.3%	7.3%	-	215	242	-11.2%	-11.2%	-
Intl	153	225	-32.0%	-26.1%	-5.9%	660	859	-23.2%	-21.2%	-2.0%
WW	212	280	-24.3%	-19.6%	-4.7%	875	1,101	-20.5%	-18.9%	-1.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency
NEUROSCIENCE										
US	645	611	5.6%	5.6%	-	2,452	2,584	-5.1%	-5.1%	-
Intl	1,006	1,040	-3.3%	5.1%	-8.4%	4,035	4,083	-1.2%	2.2%	-3.4%
WW	1,651	1,651	0.0%	5.3%	-5.3%	6,487	6,667	-2.7%	-0.6%	-2.1%
CONCERTA/METHYLPHENIDATE										
US	55	46	19.6%	19.6%	-	152	308	-50.6%	-50.6%	-
Intl	114	123	-7.3%	0.5%	-7.8%	447	474	-5.7%	-1.6%	-4.1%
WW	169	169	0.0%	5.7%	-5.7%	599	782	-23.4%	-20.9%	-2.5%
INVEGA										
US	96	87	10.3%	10.3%	-	360	316	13.9%	13.9%	-
Intl	65	67	-3.0%	7.0%	-10.0%	280	267	4.9%	8.7%	-3.8%
WW	161	154	4.5%	8.9%	-4.4%	640	583	9.8%	11.5%	-1.7%
INVEGA SUSTENNA/ XEPLION										
US	226	188	20.2%	20.2%	-	825	690	19.6%	19.6%	-
Intl	192	162	18.5%	27.8%	-9.3%	763	558	36.7%	39.1%	-2.4%
WW	418	350	19.4%	23.7%	-4.3%	1,588	1,248	27.2%	28.3%	-1.1%
RISPERDAL CONSTA										
US	104	113	-8.0%	-8.0%	-	427	440	-3.0%	-3.0%	-
Intl	190	208	-8.7%	-0.5%	-8.2%	763	878	-13.1%	-10.9%	-2.2%
WW	294	321	-8.4%	-3.1%	-5.3%	1,190	1,318	-9.7%	-8.2%	-1.5%
OTHER NEUROSCIENCE										
US	164	177	-7.3%	-7.3%	-	688	830	-17.1%	-17.1%	-
Intl	445	480	-7.3%	0.8%	-8.1%	1,782	1,906	-6.5%	-2.4%	-4.1%
WW	609	657	-7.3%	-1.4%	-5.9%	2,470	2,736	-9.7%	-6.9%	-2.8%
ONCOLOGY										
US	334	216	54.6%	54.6%	-	1,157	848	36.4%	36.4%	-
Intl	878	897	-2.1%	6.7%	-8.8%	3,300	2,925	12.8%	16.0%	-3.2%
WW	1,212	1,113	8.9%	16.0%	-7.1%	4,457	3,773	18.1%	20.6%	-2.5%
VELCADE										
US	-	-	-	-	-	-	-	-	-	-
Intl	418	524	-20.2%	-12.1%	-8.1%	1,618	1,660	-2.5%	1.1%	-3.6%
WW	418	524	-20.2%	-12.1%	-8.1%	1,618	1,660	-2.5%	1.1%	-3.6%
ZYTIGA										
US	255	211	20.9%	20.9%	-	971	750	29.5%	29.5%	-
Intl	340	284	19.7%	29.9%	-10.2%	1,266	948	33.5%	36.1%	-2.6%
WW	595	495	20.2%	26.0%	-5.8%	2,237	1,698	31.7%	33.1%	-1.4%
OTHER ONCOLOGY										
US	79	5	*	*	-	186	98	89.8%	89.8%	-
Intl	120	89	34.8%	43.9%	-9.1%	416	317	31.2%	34.2%	-3.0%
WW	199	94	*	*	-8.6%	602	415	45.1%	47.4%	-2.3%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency
TOTAL OTHER										
US	997	696	43.2%	43.2%	-	3,600	2,848	26.4%	26.4%	-
Intl	485	490	-1.0%	6.0%	-7.0%	1,977	2,097	-5.7%	-3.4%	-2.3%
WW	1,482	1,186	25.0%	27.9%	-2.9%	5,577	4,945	12.8%	13.8%	-1.0%
<u>PROCRI/EPREX</u>										
US	177	168	5.4%	5.4%	-	715	795	-10.1%	-10.1%	-
Intl	125	139	-10.1%	-3.2%	-6.9%	523	569	-8.1%	-6.2%	-1.9%
WW	302	307	-1.6%	1.5%	-3.1%	1,238	1,364	-9.2%	-8.4%	-0.8%
<u>XARELTO</u>										
US	428	271	57.9%	57.9%	-	1,522	864	76.2%	76.2%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	428	271	57.9%	57.9%	-	1,522	864	76.2%	76.2%	-
<u>OTHER</u>										
US	392	257	52.5%	52.5%	-	1,363	1,189	14.6%	14.6%	-
Intl	360	351	2.6%	9.6%	-7.0%	1,454	1,528	-4.8%	-2.4%	-2.4%
WW	752	608	23.7%	27.7%	-4.0%	2,817	2,717	3.7%	5.0%	-1.3%
TOTAL PHARMACEUTICAL										
US	4,356	3,551	22.7%	22.7%	-	17,432	13,948	25.0%	25.0%	-
Intl	3,643	3,745	-2.7%	5.8%	-8.5%	14,881	14,177	5.0%	8.3%	-3.3%
WW	<u>\$ 7,999</u>	<u>7,296</u>	9.6%	13.9%	-4.3%	<u>\$ 32,313</u>	<u>28,125</u>	14.9%	16.5%	-1.6%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency	2014	2013	Reported	% Change Operational ⁽¹⁾	Currency
MEDICAL DEVICES ^{(2),(3),(7)}										
CARDIOVASCULAR CARE										
US	\$ 222	210	5.7%	5.7%	-	\$ 862	808	6.7%	6.7%	-
Intl	336	324	3.7%	12.4%	-8.7%	1,346	1,269	6.1%	9.4%	-3.3%
WW	558	534	4.5%	9.8%	-5.3%	2,208	2,077	6.3%	8.3%	-2.0%
DIABETES CARE										
US	206	219	-5.9%	-5.9%	-	864	998	-13.4%	-13.4%	-
Intl	308	344	-10.5%	-1.5%	-9.0%	1,278	1,311	-2.5%	0.8%	-3.3%
WW	514	563	-8.7%	-3.2%	-5.5%	2,142	2,309	-7.2%	-5.3%	-1.9%
DIAGNOSTICS ⁽²⁾										
US	-	215	**	**	-	456	926	-50.8%	-50.8%	-
Intl	14	251	-94.4%	-90.5%	-3.9%	506	959	-47.2%	-44.9%	-2.3%
WW	14	466	-97.0%	-94.9%	-2.1%	962	1,885	-49.0%	-47.8%	-1.2%
ORTHOPAEDICS										
US	1,339	1,307	2.4%	2.4%	-	5,197	5,074	2.4%	2.4%	-
Intl	1,102	1,149	-4.1%	3.3%	-7.4%	4,478	4,435	1.0%	3.5%	-2.5%
WW	2,441	2,456	-0.6%	2.8%	-3.4%	9,675	9,509	1.7%	2.9%	-1.2%
SPECIALTY SURGERY/OTHER ⁽²⁾										
US	425	422	0.7%	0.7%	-	1,679	1,664	0.9%	0.9%	-
Intl	479	507	-5.5%	2.1%	-7.6%	1,862	1,840	1.2%	4.9%	-3.7%
WW	904	929	-2.7%	1.5%	-4.2%	3,541	3,504	1.1%	3.0%	-1.9%
SURGICAL CARE										
US	567	599	-5.3%	-5.3%	-	2,221	2,294	-3.2%	-3.2%	-
Intl	1,005	1,040	-3.4%	4.0%	-7.4%	3,955	3,975	-0.5%	2.6%	-3.1%
WW	1,572	1,639	-4.1%	0.6%	-4.7%	6,176	6,269	-1.5%	0.5%	-2.0%
VISION CARE										
US	195	228	-14.5%	-14.5%	-	975	1,036	-5.9%	-5.9%	-
Intl	451	491	-8.1%	1.7%	-9.8%	1,843	1,901	-3.1%	1.7%	-4.8%
WW	646	719	-10.2%	-3.5%	-6.7%	2,818	2,937	-4.1%	-1.0%	-3.1%
TOTAL MEDICAL DEVICES										
US	2,954	3,200	-7.7%	-7.7%	-	12,254	12,800	-4.3%	-4.3%	-
Intl	3,695	4,106	-10.0%	-2.3%	-7.7%	15,268	15,690	-2.7%	0.5%	-3.2%
WW	\$ 6,649	7,306	-9.0%	-4.7%	-4.3%	\$ 27,522	28,490	-3.4%	-1.6%	-1.8%

* Percentage greater than 100%

** Not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Reflects Diagnostics divestiture June 30, 2014

(6) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently

(7) Previously referred to as Medical Devices and Diagnostics